Strados Labs, Growing Medtech Company, Raises $4.5M In Pre-Series A Funding Round
01/05/22, 9:01 AM
Location
philadelphiaMoney raised
$4.5 million
Round Type
pre-series a
Strados Labs, a medical technology company harnessing the power of smart sensors, machine learning and proprietary algorithms to provide early detection and predictions of worsening respiratory diseases, today announced its pre-series A round of funding at $4.5M. Investors in the round included SOSV, cultivate(MD), Wavemaker360 Health, Blu Venture Investors and Broad Street Angels.
Company Info
Location
philadelphia, pennsylvania, united states
Additional Info
Strados Labs is a medical technology company developing smart sensor platforms that utilize machine learning and proprietary algorithms to detect and predict compounding conditions associated with serious, chronic respiratory diseases to improve the lives of patients globally. The Company developed a first-of-its-kind smart sensor platform for respiratory health, RESPTM. Strados was recently granted a CE Mark for RESPTM and received its FDA Class II 510(k) clearance for it last December. The Company is developing a robust pipeline of other smart sensor platforms to support and address other chronic diseases, as well as chronic disease management. Strados will continue to target asthma, COPD and infectious respiratory diseases (COVID, RSV, etc.) as it moves into 2022—with plans to add heart failure in late 2022. The Company is based in Philadelphia and is a privately held company. For more information, visit: stradoslabs.com